{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T15:47:31Z","timestamp":1772120851996,"version":"3.50.1"},"reference-count":28,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,24]],"date-time":"2021-11-24T00:00:00Z","timestamp":1637712000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.esmoop.2021.100350","type":"journal-article","created":{"date-parts":[[2021,11,27]],"date-time":"2021-11-27T00:28:39Z","timestamp":1637972919000},"page":"100350","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study"],"prefix":"10.1016","volume":"7","author":[{"given":"E.M.","family":"Ruggeri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8374-1362","authenticated-orcid":false,"given":"F.","family":"Nelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Onorato","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Giannarelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.R.","family":"Giron Berrios","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Virtuoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Marrucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Mazzotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Schirripa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Panichi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pessina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Signorelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Chilelli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Primi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Natoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Fazio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.A.","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmoop.2021.100350_bib1","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S1470-2045(20)30175-3","article-title":"COVID-19: global consequences for oncology","volume":"21","author":"The Lancet Oncology","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib2","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1093\/jnci\/djaa159","article-title":"Prevalence and outcome of COVID-19 infection in cancer patients: a national Veterans Affairs study","volume":"113","author":"Fillmore","year":"2020","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.esmoop.2021.100350_bib3","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1001\/jamaoncol.2020.6178","article-title":"Analyses of risk, racial disparity, and outcomes among US patients with cancer and COVID-19 infection","volume":"7","author":"Wang","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib4","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1038\/s41591-020-0979-0","article-title":"Determinants of COVID-19 disease severity in patients with cancer","volume":"26","author":"Robilotti","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.esmoop.2021.100350_bib5","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov"},{"key":"10.1016\/j.esmoop.2021.100350_bib6","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.canlet.2021.02.012","article-title":"Epidemiological and clinical characteristics of cancer patients with COVID-19: a systematic review and meta-analysis of global data","volume":"508","author":"Kong","year":"2021","journal-title":"Cancer Lett"},{"key":"10.1016\/j.esmoop.2021.100350_bib7","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100350_bib8","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.esmoop.2021.100350_bib9","first-page":"S0923","article-title":"Effects of active cancer treatment on safety and immunogenicity of COVID-19 mRNA-BNT162b2 vaccine: preliminary results from the prospective observational Vax-On study","volume":"20","author":"Nelli","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib12","author":"AdviseDx SARS-CoV-2 IgG II"},{"key":"10.1016\/j.esmoop.2021.100350_bib13","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/j.annonc.2021.04.020","article-title":"Weak immunogenicity after a single dose of SARS-CoV-2 mRNA vaccine in treated cancer patients","volume":"32","author":"Palich","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib14","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1016\/j.annonc.2021.04.019","article-title":"Impaired immunogenicity of BNT162b2 anti-SARS-CoV-2 vaccine in patients treated for solid tumors","volume":"32","author":"Barri\u00e8re","year":"2021","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib15","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/j.ccell.2021.06.009","article-title":"Immunogenicity of SARS-CoV-2 messenger RNA vaccines in patients with cancer","volume":"39","author":"Addeo","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2021.100350_bib16","doi-asserted-by":"crossref","first-page":"6815","DOI":"10.1158\/1078-0432.CCR-21-2439","article-title":"Immunogenicity and safety of COVID-19 vaccine BNT162b2 for patients with solid cancer: a large cohort prospective study from a single institution","volume":"27","author":"Di Noia","year":"2021","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.esmoop.2021.100350_bib17","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamaoncol.2021.2155","article-title":"Evaluation of seropositivity following BNT162b2 Messenger RNA vaccination for SARS-CoV-2 in patients undergoing treatment for cancer","volume":"7","author":"Massarweh","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib18","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.ccell.2021.06.002","article-title":"Seroconversion rates following COVID-19 vaccination among patients with cancer","volume":"39","author":"Thakkar","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2021.100350_bib19","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/S1470-2045(21)00213-8","article-title":"Safety and immunogenicity of one versus two doses of the COVID-19 vaccine BNT162b2 for patients with cancer: interim analysis of a prospective observational study","volume":"22","author":"Monin","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib20","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1001\/jamaoncol.2021.2675","article-title":"Serologic status and toxic effects of the SARS-CoV-2 BNT162b2 vaccine in patients undergoing treatment for cancer","volume":"7","author":"Goshen-Lago","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib21","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.ccell.2021.07.016","article-title":"Antibody and T cell immune responses following mRNA COVID-19 vaccination in patients with cancer","volume":"39","author":"Ehmsen","year":"2021","journal-title":"Cancer Cell"},{"key":"10.1016\/j.esmoop.2021.100350_bib22","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00262-019-02449-y","article-title":"Chemotherapy markedly reduces B cells but not T cells and NK cells in patients with cancer","volume":"69","author":"Waidhauser","year":"2020","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.esmoop.2021.100350_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.trecan.2016.11.009","article-title":"Targeted therapy and immunosuppression in the tumor microenvironment","volume":"3","author":"Allegrezza","year":"2017","journal-title":"Trends Cancer"},{"key":"10.1016\/j.esmoop.2021.100350_bib24","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1093\/annonc\/mdr141","article-title":"Immunogenicity and safety of the influenza A H1N1v 2009 vaccine in cancer patients treated with cytotoxic chemotherapy and\/or targeted therapy: the VACANCE study","volume":"23","author":"Rousseau","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.esmoop.2021.100350_bib25","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/S2352-3026(21)00169-1","article-title":"Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study","volume":"8","author":"Maneikis","year":"2021","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.esmoop.2021.100350_bib26","doi-asserted-by":"crossref","first-page":"2618","DOI":"10.1016\/j.cell.2021.03.051","article-title":"TOP1 inhibition therapy protects against SARS-CoV-2-induced lethal inflammation","volume":"184","author":"Ho","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.esmoop.2021.100350_bib27","doi-asserted-by":"crossref","first-page":"100283","DOI":"10.1016\/j.esmoop.2021.100283","article-title":"Serologic response to COVID-19 infection and\/or vaccine in cancer patients on active treatment","volume":"6","author":"Grinshpun","year":"2021","journal-title":"ESMO Open"},{"key":"10.1016\/j.esmoop.2021.100350_bib28","doi-asserted-by":"crossref","first-page":"1758004","DOI":"10.1080\/2162402X.2020.1758004","article-title":"Dexamethasone premedication suppresses vaccine-induced immune responses against cancer","volume":"9","author":"Vormehr","year":"2020","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.esmoop.2021.100350_bib29","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/S2213-2600(21)00220-4","article-title":"BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers","volume":"9","author":"Lustig","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.esmoop.2021.100350_bib30","first-page":"1","article-title":"Immunological surrogate endpoints of COVID-2019 vaccines: the evidence we have versus the evidence we need","volume":"6","author":"Jin","year":"2021","journal-title":"Signal Transduct Target Ther"}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003124?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921003124?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:27:34Z","timestamp":1761856054000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921003124"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S2059702921003124"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100350","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.741363445.793591179","asserted-by":"object"}]},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antineoplastic treatment class modulates COVID-19 mRNA-BNT162b2 vaccine immunogenicity in cancer patients: a secondary analysis of the prospective Vax-On study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100350","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100350"}}